Emerging Market Earnings Roundup: China Surpasses Japan As AstraZeneca’s Second Largest Market (Part 4)
This article was originally published in PharmAsia News
Executive Summary
China is now AstraZeneca’s second largest market where it out grew multinational peers including Pfizer in the first quarter.
You may also be interested in...
AstraZeneca’s Soriot Says Mega-Mergers Can Work, But Is Hush Hush On Pfizer
AstraZeneca did not address rumors it has become an acquisition target of Pfizer during its first quarter conference call. CEO Soriot did say that some mega-mergers can work, but such deals have to be evaluated on a case-by-case basis.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.